Below are the most recent publications written about "Mycophenolic Acid" by people in Profiles.
-
Asare E, Du T, Xie H, Liang D, Gao S. Biopharmaceutical Factors Involved in the Disposition of Mycophenolic Acid: A Comprehensive Review of ADME Properties and Their Potential Impact on Mycophenolic Acid Plasma Exposure. Curr Drug Metab. 2025; 26(3):159-172.
-
Harrison DE, Strong R, Reifsnyder P, Rosenthal N, Korstanje R, Fernandez E, Flurkey K, Ginsburg BC, Murrell MD, Javors MA, Lopez-Cruzan M, Nelson JF, Willcox BJ, Allsopp R, Watumull DM, Watumull DG, Cortopassi G, Kirkland JL, Tchkonia T, Choi YG, Yousefzadeh MJ, Robbins PD, Mitchell JR, Acar M, Sarnoski EA, Bene MR, Salmon A, Kumar N, Miller RA. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. Geroscience. 2024 02; 46(1):795-816.
-
L?pez-Oliva MO, P?rez-Flores I, Molina M, Jos? Aladr?n M, Trujillo H, Redondo-Pach?n D, L?pez V, Facundo C, Villanego F, Rodr?guez M, Carmen Ruiz M, Ant?n P, Rivas-Oural A, Cabello S, Portol?s J, de la Vara L, Tabernero G, Valero R, Galeano C, Moral E, Ventura A, Coca A, ?ngel Mu?oz M, Hern?ndez-Gallego R, Shabaka A, Ledesma G, Bouarich H, ?ngeles Rodr?guez M, P?rez Tamaj?n L, Cruzado L, Emilio S?nchez J, Jim?nez C. Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology COVID registry. Nefrologia (Engl Ed). 2023 Jul-Aug; 43(4):442-451.
-
Etim I, Abasifreke B, Sun R, Kuddabujja D, Liang D, Du T, Gao S. Development of a novel UPLC-MS/MS method for the simultaneous quantification of mycophenolic mofetil, mycophenolic acid, and its major metabolites: Application to pharmacokinetic and tissue distribution study in rats. J Pharm Biomed Anal. 2023 Sep 20; 234:115504.
-
Pascual J, Jim?nez C, Krajewska M, Seron D, Kotton CN, Portol?s J, Witzke O, Sorensen SS, Andr?s A, Crespo M, Paz-Artal E, D?ez T, Ortega A, Portero I. The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients. Transpl Immunol. 2022 12; 75:101711.
-
Martin-Moreno PL, S?nchez-Fructuoso AI, Mazuecos A, Mir M, Lopez-Lopez I, Gonz?lez-Rinne A, Coca A, Valero R, Ventura Galiano A, Ridao N, Toapanta-Gaibor NG, Fern?ndez-Tagarro E, Cruzado-Vega L, P?rez-Mir M, Jim?nez C. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. Clin Transplant. 2021 05; 35(5):e14256.
-
Gao X, Tsai RYL, Ma J, Bhupal PK, Liu X, Liang D, Xie H. Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 01; 1136:121930.
-
Mundisugih J, Fernando H, Bergin P, Hare J, Kaye D, Leet A, McGiffin D, Taylor AJ. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction. Prog Transplant. 2019 12; 29(4):327-334.
-
Hsu WT, Lin CH, Jui HY, Tseng YH, Shun CT, Hsu MC, Wu KK, Lee CM. CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen. Transplantation. 2018 12; 102(12):2002-2011.
-
Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006 Sep 15; 108(6):1965-71.